Moreover, further phase I clinical trials (NCT02454010) studies suggest the use of P-cadherin-targeted radioimmunotherapy with Y-FF-21101 monoclonal antibody in the treatment of solid tumours as showing promising results [119]; however, this treatment has not been tested in breast cancer patients, which might be an interesting approach for the future since P-cadherin overexpression is a common feature of breast cancer patients. This evidence concerns the gene CDH3 and breast carcinoma.